Genocea Biosciences, Inc. GNCA
We take great care to ensure that the data presented and summarized in this overview for GENOCEA BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GNCA
View allLatest Institutional Activity in GNCA
Top Purchases
Top Sells
About GNCA
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Insider Transactions at GNCA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
4,023
-1.3%
|
$0
$0.06 P/Share
|
|
Jun 02
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,578
-1.74%
|
$0
$0.06 P/Share
|
|
Jun 02
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,355
-1.77%
|
$0
$0.06 P/Share
|
|
Jun 01
2022
|
Jacquelyn L Sumer CHIEF LEGAL & COMPLIANCE OFF |
SELL
Open market or private sale
|
Direct |
2,500
-5.49%
|
$0
$0.06 P/Share
|
|
May 31
2022
|
William D Clark President and CEO |
SELL
Open market or private sale
|
Direct |
117,244
-27.55%
|
$0
$0.06 P/Share
|
|
May 27
2022
|
George Siber Director |
SELL
Open market or private sale
|
Direct |
20,425
-98.78%
|
$0
$0.07 P/Share
|
|
May 26
2022
|
Diantha Duvall CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
24,407
-24.13%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Jessica Baker Flechtner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,525
-15.43%
|
$0
$0.09 P/Share
|
|
May 25
2022
|
Raymond D Stapleton Jr CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-5.41%
|
$0
$0.09 P/Share
|
|
May 25
2022
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Ali Behbahani Director |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Carmen Chang > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Anthony A. Florence Jr. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Mohamad Makhzoumi > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
New Enterprise Associates 16, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Peter W. Sonsini > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 25
2022
|
Paul Edward Walker > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,445,093
-100.0%
|
$0
$0.08 P/Share
|
|
May 24
2022
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|
|
May 24
2022
|
Ali Behbahani Director |
SELL
Open market or private sale
|
Indirect |
5,931,843
-57.16%
|
$0
$0.07 P/Share
|